Allergen‐Specific IgE is a Stronger Predictor of Remission Following Peanut Oral Immunotherapy Than Age in Children Aged 1–10 Years
Allergy · 2025
DOI: 10.1111/all.16451 ↗At a glance
Randomisierte kontrollierte Studie in Allergy, 2025. Written by Sarah E Ashley and 8 co-authors. Institution: Murdoch Children's Research Institute, Parkville, Australia. Major MEDLINE topics: Peanut Hypersensitivity, Allergens, Desensitization, Immunologic, Immunoglobulin E. Cited 16 times so far (Crossref); 18 references. The full text is freely available (open access, CC BY 4.0).
Topics: Kinderkrankenpflege
Abstract (original language)
Background
Remission is the desired outcome following OIT as it allows individuals to discontinue treatment and eat the allergen freely. Early initiation of OIT in infants and toddlers has been embraced as an approach to increase the likelihood of remission. However, there is no high‐quality evidence supporting younger age as an independent factor driving remission; available studies are limited by small samples of younger subjects and lack of adjustment for confounding covariates, particularly peanut‐specific IgE (sIgE) levels which is closely correlated with age.
Methods
This study examined relationships between peanut sIgE and age at baseline and remission, in children aged 1–10 who completed 18 months of OIT in the PPOIT‐003 RCT ( n = 162). Remission was defined as absence of clinical reactivity to peanut after 8 weeks of allergen avoidance/treatment discontinuation. Age and sIgE were examined as continuous variables in univariate and multivariate regression models.
Results
Higher peanut sIgE was consistently predictive of lower likelihood of remission, independent of age. In contrast, there was no independent association between age and remission after adjusting for baseline sIgE (OR 0.94 [0.79–1.12], p = 0.5).
Conclusions
Findings do not support age as an independent predictor of remission following OIT. Additional studies examining safety and efficacy of OIT in infants and younger children are urgently needed, ahead of widespread adoption of early intervention.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Murdoch Children's Research Institute, Parkville, Australia.
- The University of Melbourne, Parkville, Australia.
- The Royal Children's Hospital Melbourne, Parkville, Australia.
- Monash University Parkville Campus, Parkville, Australia.
- Monash Children's Hospital, Clayton, Australia.
- Telethon Kids Institute, Nedlands, Australia.
ORCID profiles: Sarah E Ashley, Paxton Loke
Cite
APA
Ashley, S. E., Lloyd, M., Loke, P., Orsini, F., Lozinsky, A. C., O'Sullivan, M. D., Quinn, P., Gold, M., & Tang, M. L. K. (2025). Allergen‐Specific IgE is a Stronger Predictor of Remission Following Peanut Oral Immunotherapy Than Age in Children Aged 1–10 Years. Allergy. https://doi.org/10.1111/all.16451
Vancouver
Ashley SE, Lloyd M, Loke P, Orsini F, Lozinsky AC, O'Sullivan MD, et al. Allergen‐Specific IgE is a Stronger Predictor of Remission Following Peanut Oral Immunotherapy Than Age in Children Aged 1–10 Years. Allergy. 2025. doi:10.1111/all.16451
BibTeX
@article{Ashley2025,
author = {Ashley, Sarah E and Lloyd, Melanie and Loke, Paxton and Orsini, Francesca and Lozinsky, Adriana C and O'Sullivan, Michael D and Quinn, Patrick and Gold, Michael and Tang, Mimi L K},
title = {Allergen‐Specific IgE is a Stronger Predictor of Remission Following Peanut Oral Immunotherapy Than Age in Children Aged 1–10 Years},
journal = {Allergy},
year = {2025},
doi = {10.1111/all.16451}
}
EUVIMED